TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15102339
Drug: Celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (Celebrex) 200 mg
Study: 14504565
Drug: l-tryptophan
Normalized name: L-tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: l-tryptophan
Study: 361988
Drug: Prazosin and
Normalized name: prazosin and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin and diuretics
Study: 361988
Drug: Clonidine and
Normalized name: clonidine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine and diuretics
Study: 21377168
Drug: Hybrid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid treatment (SCST and neurocognitive remediation)
Study: 19646443
Drug: Lanreotide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (120 mg) administered every 28 days for 24 weeks
Study: 11318525
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of IFN‐beta twice daily for four weeks (group A)
Study: 9007770
Drug: Short CPM
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short CPM duration (3-5 hours per day) with CPM ROM increased 5 degrees twice daily
Study: 9007770
Drug: Short CPM
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short CPM duration with CPM ROM increased daily to patient tolerance
Study: 9007770
Drug: Long CPM
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long CPM duration (10-12 hours per day) with CPM ROM increased 5 degrees twice daily
Study: 9007770
Drug: Long CPM
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long CPM duration with CPM ROM increased daily to patient tolerance
Study: 8110435
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.5 g/day) for 8 weeks
Study: 27678295
Drug: Vigil (1.0×10^7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigil (1.0×10^7 cells/intradermal injection/month for 4 to 12 doses)
Study: 19940012
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily) with FOLFOX plus 5 mg/kg bevacizumab
Study: 19940012
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily) with FOLFOX plus 2 mg/kg bevacizumab
Study: 19940012
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily) with FOLFIRI
Study: 19940012
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily) with FOLFOX
Study: 18981327
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 to 32 mg)
Study: 18981327
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 to 50 mg)
Study: 12166578
Drug: Continuous oxygen
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oxygen therapy (COT) > or = 15 h daily
Study: 12166578
Drug: Noncontinuous oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontinuous oxygen therapy (NCOT) <15 h daily
Study: 25467591
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 12 weeks
Study: 25467591
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) with ribavirin for 18 weeks
Study: 25467591
Drug: Grazoprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazoprevir (100 mg daily) and Elbasvir (50 mg daily) without ribavirin for 12 weeks
Study: 7868711
Drug: 250 mg/day
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/day terbinafine
Study: 21103938
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day itraconazole
Study: 17080254
Drug: L-acetylcarnitine (LAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (LAC), n=13
Study: 11711355
Drug: Abarelix 100
Normalized name: abarelix 100 mg INTRAMUSC VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abarelix 100 mg
Study: 7957455
Drug: microencapsulated potassium
Normalized name: Microencapsulated potassium chloride 15 MEQ Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: microencapsulated potassium chloride tablet (MET)
Study: 7957455
Drug: potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: potassium chloride solution (PS)
Study: 7957455
Drug: microencapsulated potassium
Normalized name: Microencapsulated potassium chloride 15 MEQ Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: microencapsulated potassium chloride capsules (MEC)
Study: 28327694
Drug: SurfLink-treated titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SurfLink-treated titanium dental implants
Study: 28327694
Drug: Untreated control
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated control titanium dental implants
Study: 22008390
Drug: High-dose UFH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UFH (100 units kg(‐1) bolus, followed by 20 units kg h(‐1) continuous infusion)
Study: 22008390
Drug: Low-dose UFH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UFH (50 units kg(‐1) bolus)
Study: 22008390
Drug: High-dose UFH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UFH
Study: 22008390
Drug: Low-dose UFH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UFH
Study: 19428087
Drug: Pelvic plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic plexus block with 2 mL of 2% lidocaine
Study: 19428087
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve block (PPNB) with 2 mL of 2% lidocaine
Study: 16716214
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (100 mg daily for 5 days)
Study: 16716214
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose aspirin (325 mg daily for 5 days)
Study: 16716214
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin vs Medium dose aspirin
Study: 9389342
Drug: ASTED system
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTED system for sample preparation prior to HPLC
Study: 7906473
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol (0.5%) administered 5-6 hours before surgery
Study: 7906473
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol (0.5%) administered 12 hours before surgery
Study: 7906473
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol (0.5%) administered 24 hours before surgery
Study: 7906473
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol (0.5%) administered 48 hours before surgery
Study: 7906473
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol (0.5%) administered 4 hours before surgery into the contralateral eye
Study: 2886529
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 500 mg metronidazole
Study: 2886529
Drug: Zero, two,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zero, two, three, six, or twenty-one doses of metronidazole
Study: 25421542
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid administered once during preoperative hormonal therapy with letrozole for 24 weeks
Study: 22401913
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine oestrogen (0.625 mg per day)
Study: 20885291
Drug: Scvo2-guided fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scvo2-guided fluid therapy (crystalloid infusion 100 ml/h, bolus of 3 ml/kg hydroxyethyl starch if Scvo2 < 75%)
Study: 20885291
Drug: Traditional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional fluid regimen (crystalloid 800 ml/h, extra fluid for clinical signs of hypovolemia)
Study: 17138193
Drug: Radial nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial nerve injection (group RAD)
Study: 17138193
Drug: Ulnar nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulnar nerve injection (group ULN)
Study: 14732882
Drug: Biochemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemotherapy regimens combining IL‐2, IFN‐alpha and chemotherapy
Study: 14732882
Drug: Cytokines alone
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines alone (IL‐2 as a single agent or in combination with IFN‐alpha)
Study: 14732882
Drug: Immunotherapy alone
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy alone with additions (histamine or vaccines to IL‐2)
Study: 10761967
Drug: 3-g ginseng
Normalized name: PANAX GINSENG WHOLE 0.3 g ORAL CAPSULE [Mirapharm-22]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-g ginseng taken 40 minutes before glucose challenge
Study: 10761967
Drug: 3-g ginseng
Normalized name: PANAX GINSENG WHOLE 0.3 g ORAL CAPSULE [Mirapharm-22]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-g ginseng taken together with glucose challenge
Study: 10761967
Drug: 3-g ginseng
Normalized name: PANAX GINSENG WHOLE 0.3 g ORAL CAPSULE [Mirapharm-22]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-g ginseng taken before glucose challenge
Study: 8672407
Drug: Fat-replaced meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-replaced meal (3305 kJ, 54.6 g SPE, 24 g fat)
Study: 8672407
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (5192 kJ, 73.2 g fat)
Study: 1599343
Drug: Nonpharmacologic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonpharmacologic intervention (weight reduction, sodium restriction, increased physical activity) consisting of eight weekly group sessions and two individual sessions followed by four monthly group sessions.
Study: 6532149
Drug: Response prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response prevention treatment
Study: 6532149
Drug: Rapid smoking
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid smoking comparison treatment
Study: 30616899
Drug: Coaching care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching care (CC) with weekly phone calls for 3 months
Study: 24786935
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (self-administered)
Study: 22462640
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (25(OH)D < 50 nmol/l) at 24-26 weeks of gestation
Study: 8878218
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms Engerix-B vaccine
Study: 8878218
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms Engerix-B vaccine
Study: 2049750
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) plus prednisolone (PRDLN) (5 mg twice daily)
Study: 2049750
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) (10 mg twice daily) plus placebo
Study: 30723140
Drug: Letrozole plus
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole plus Alpelisib (2.5 mg/day letrozole with 300 mg/day alpelisib for 24 weeks)
Study: 17931925
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL 0.5% bupivacaine with 1:200,000 epinephrine
Study: 17931925
Drug: 1.8 mL
Normalized name: insulin pump syringe, 1.8 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mL 2% lidocaine with 1:100,000 epinephrine
Study: 9462439
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg iv tds for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Study: 9462439
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg iv bd for 48-72 h followed by oral cefuroxime axetil 500 mg bd for 5-7 days
Study: 8170877
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin and nitroglycerin (GTN) at a constant dose of 16.6 micrograms/minute
Study: 8170877
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin and isosorbide dinitrate at a constant dose of 33.3 micrograms/minute
Study: 8170877
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received identical doses of heparin
Study: 29474893
Drug: Personalized bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized bronchodilator dosing
Study: 29474893
Drug: Fixed bronchodilator
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed bronchodilator dosing
Study: 21397720
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine with GM-CSF
Study: 21397720
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine without GM-CSF
Study: 21397720
Drug: GM-CSF receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF receptor expression
Study: 18286870
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (long-term use)
Study: 18286870
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (HIV control group)
Study: 16545330
Drug: Stediril 30
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stediril 30 (oral contraceptive containing levonorgestrel)
Study: 11261274
Drug: High-dose consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose consolidation therapy
Study: 6282024
Drug: Captopril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (200 mg)
Study: 29394175
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of low‐ and high‐frequency stimulations (n = 8)
Study: 27032884
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTX‐A) injection after ESD
Study: 24395980
Drug: Not treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not treated with β-blockers
Study: 21383686
Drug: Upfront therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront therapy for aGVHD
Study: 21383686
Drug: No response
Approvals — FDA: no, EMA: no, PMDA: no
Description: No response to therapy by day 28
Study: 25061313
Drug: Aliskiren-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren-based therapy
Study: 17464949
Drug: High-dose ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ifosfamide (12 g/m(2)/cycle)
Study: 17464949
Drug: Standard-dose ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose ifosfamide (6 g/m(2)/cycle)
Study: 8730122
Drug: rIFN-gamma 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma 0.01 mg/m2/day for 1 week, followed by 0.1 mg/m2/day intramuscularly for 18 weeks
Study: 7091876
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg orally)
Study: 21239519
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (10 mg) with GH (0.6 mg/d)
Study: 21239519
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone (40 mg) with GH (0.6 mg/d)
Study: 21239519
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy alone
Study: 21239519
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (10 mg)
Study: 21239519
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone (40 mg)
Study: 12528101
Drug: Adalimumab 20
Normalized name: ADALIMUMAB 20MG/0.4ML INJ SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 20 mg plus MTX
Study: 12528101
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg plus MTX
Study: 12528101
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg plus MTX
Study: 8899499
Drug: IFN-alpha, 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, 16 million U1 intramuscularly daily for 2 weeks, then three times a week
Study: 8899499
Drug: IFN-alpha, 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, 24 weeks treatment
Study: 8899499
Drug: IFN-alpha, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, 40 weeks treatment
Study: 8899499
Drug: IFN-alpha, long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, long-term treatment
Study: 8899499
Drug: IFN-alpha, treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, treatment for HCV-RNA genotype 1b and 2a or 2b
Study: 8899499
Drug: IFN-alpha, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha, 40 weeks treatment for patients with mild liver tissue damage or low virus counts
Study: 2056598
Drug: 11 ml
Normalized name: camphor 0.11 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 ml 2% lidocaine jelly
Study: 2056598
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 2% lidocaine jelly
Study: 27864694
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks for the first 6 of 8 cycles and for 10 doses postoperatively)
Study: 22533496
Drug: Bedtime dose
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime dose of ARB
Study: 22533496
Drug: Morning dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dose of ARB
Study: 18708615
Drug: Ruboxistaurin (RBX)
Normalized name: ethanol
DrugBank: Ruboxistaurin (DB11829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruboxistaurin (RBX) 32 mg/d
Study: 17575470
Drug: 12‐week treadmill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐week treadmill exercise program (target lactate 2.5 +/‐ 0.5 mmol/l)
Study: 15735183
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with insulin aspart
Study: 15220227
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI) with once-daily glargine and premeal/snack insulin aspart
Study: 21169170
Drug: 8-week therapist-assisted
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week therapist-assisted Web-based treatment
Study: 17711615
Drug: Case formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case formulation (CF) in cognitive behaviour therapy
Study: 14616330
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV (O4)
Study: 14616330
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg IV (O8)
Study: 10819278
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (500,000 KIU)
Study: 10819278
Drug: Medium-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose aprotinin (1,000,000 KIU load, 250,000 KIU/hr infusion)
Study: 10819278
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin (2,000,000 KIU load, 500,000 KIU/hr infusion)
Study: 10819278
Drug: Aprotinin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (all doses combined)
Study: 9087576
Drug: Cold crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold crystalloid cardioplegic solution
Study: 9087576
Drug: Cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold blood cardioplegic solution
Study: 8442967
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg diluted in 10 ml saline)
Study: 8442967
Drug: Epidural lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lidocaine (10 ml of 2% lidocaine)
Study: 31862447
Drug: Surgical procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical procedure for treatment of intermittent exotropia in children aged 3 to <5 years.
Study: 31862447
Drug: Surgical procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical procedure for treatment of intermittent exotropia in children aged 5 to <11 years.
Study: 31509993
Drug: Human Animal
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Animal Interaction with therapy dogs only (100% HAI)
Study: 27339738
Drug: obinutuzumab or
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: obinutuzumab or rituximab induction therapy (IT) for 4 weeks